Tekrardan Hoşgeldiniz
Cointime’a Katıl
Giriş Yap
Kayıt Ol
Gelen kutunuzu kontrol edin
Acer Therapeutics
About
Acer Therapeutics focuses on the acquisition, development, and commercialization of therapies for patients with serious rare diseases.
- Newton,Massachusetts,United States
- 11 - 50
- http://www.acertx.com/
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $1.50M
- Industries
- Biotechnology,Medical,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2013
- Number Of Employee
- 11 - 50
- Operating Status
- Active
- Stock Symbol
- nasdaq:ACER
- Legal Name
- Acer Therapeutics Inc.
Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 30, 2022 | Post-IPO Equity | $1.50M | — | — | — | Detail |
| Mar 7, 2022 | Post-IPO Debt | $48.50M | 2 | — | — | Detail |
| Sep 19, 2017 | Post-IPO Equity | $15.70M | 1 |
TVM Capital Life Science
|
— | Detail |
| Sep 19, 2017 | IPO | — | — | — | — | Detail |
| May 6, 2016 | Post-IPO Equity | $8.14M | 1 |
TVM Capital Life Science
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
TVM Capital Life Science
|
Yes | Post-IPO Equity |
Marathon Asset Management
|
— | Post-IPO Debt |
SWK Holdings
|
— | Post-IPO Debt |
Employee Profiles
Acquisition
Acer Therapeutics has acquired 1 organizations. Their most recent acquisition was Opexa Therapeutics on Sep 19, 2017. They acquired Opexa Therapeutics for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Sep 19, 2017
Opexa Therapeutics
|
Biotechnology | merge | — | Detail |
